Ann Dermatol.  2008 Sep;20(3):162-165. 10.5021/ad.2008.20.3.162.

Recurrent Classical Type of Kaposi's Sarcoma Treated by Interferon-alpha

• Kang MJ
• Kim TY

• KMID: 2156386
• DOI: http://doi.org/10.5021/ad.2008.20.3.162

Abstract

Kaposi's sarcoma (KS) is a lympho-angioproliferative disease, with four variants; one of which is classical KS (CKS). Classical KS is clinically characterized by single or multiple pea-sized bluish-red macules on the distal portions of the lower extremities. A 60-year-old man presented with an asymptomatic, solitary patch on the left sole. He had been successfully treated for the classical type of Kaposi sarcoma on the right sole with interferon-alpha 3 years before. The patient was treated with six million units of interferon-alpha three times per week for 6 months. The lesion showed complete resolution and there has been no report of recurrence for 1 year after treatment.

Keyword

Interferon-alpha; Kaposi's sarcoma

MeSH Terms

Humans
Interferon-alpha
Lower Extremity
Middle Aged
Recurrence
Sarcoma, Kaposi
Interferon-alpha

Figure

• 

  Fig. 1 (A) First visit - mildly tender, erythematous, 1.2 cm sized nodule and satellite purplish macules and papules are observed on the sole. (B) Second visit - an asymptomatic, solitary, purplish patch is seen on the left sole. (C) Spindle cells forming slit-like spaces occupied by red blood cells and endothelial proliferation in the dermis (H&E stain, ×40; inlet, ×200). This histopathologic characteristic was found in both A and B lesions

• 

  Fig. 2 (A, B) Normal appearance of both soles after the second interferon-α treatment course. (C) A biopsy of the resolving lesion shows mild perivascular lymphohistiocytic infiltration in the dermis (H&E stain, ×40)

Reference

1. Aldenhoven M, Barlo NP, Sanders CJ. Therapeutic strategies for epidemic Kaposi's sarcoma. Int J STD AIDS. 2006; 17:571–508.

2. Costa da Cunha CS, Lebbe C, Rybojad M, Agbalika F, Ferchal F, Rabian C, et al. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon α-2b. Arch Dermatol. 1996; 132:285–290.

3. Caccialanza M, Marca S, Piccinno R, Eulisse G. Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol. 2008; 22:297–302.

4. Luppi M, Barozzi P, Rasini V, Riva G, Re A, Rossi G, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation. 2002; 74:131–132.

5. Corbellino M, Bestetti G, Scalamonga C, Calattini S, Galazzi M, Meroni L, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001; 98:3473–3475.

6. Gheith O, Bakr A, Wafa E, Fouda A, El Agroudy A, Refaie A, et al. Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal transplant recipient. Clin Exp Nephrol. 2007; 11:251–254.

7. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res. 2002; 22:295–303.

8. Tardivo JP, Del Giglio A, Paschoal LH, Baptista MS. New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma. Photomed Laser Surg. 2006; 24:528–531.

9. Cianfrocca M, Roenn JH. Epidemic Kaposi's sarcoma. Oncology. 1998; (12):1375–1381.